Donna S Zhukovsky1,2, Cathy L Rozmus3, Rhonda S Robert2, Eduardo Bruera1, Robert J Wells2, Gary B Chisholm4, Julio A Allo1, Marlene Z Cohen5. 1. Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. School of Nursing, The University of Texas Health Science Center at Houston, Houston, Texas. 4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. College of Nursing, The University of Nebraska Medical Center, Omaha, Nebraska.
Abstract
BACKGROUND: Systematic symptom assessment is not routinely performed in pediatric oncology. The objectives of the current study were to characterize the symptoms of pediatric oncology outpatients and evaluate agreement between patient and proxy reports and the association between children's ratings and oncologists' treatment recommendations. METHODS: Two versions of the pediatric Memorial Symptom Assessment Scale (pMSAS) were translated into Spanish. An age-appropriate and language-appropriate pMSAS was administered independently before visits to the oncologist to patients and family caregivers (caregivers) and after visits to consenting oncologists. Statistical analysis included Spearman correlation coefficients and weighted kappa values. RESULTS: English and Spanish results were similar and were combined. A total of 60 children and their caregivers completed the pMSAS. The children had a median age of 10 years (range, 7-18 years); approximately 62% were male and 33% were Spanish-speaking. Fourteen oncologists completed the pMSAS for 25 patients. Nine patients (15%) had no symptoms and 38 patients (63%) reported ≥2 symptoms. The most common symptoms were fatigue (12 patients; 40%) and itch (9 patients; 30%) for the younger children and pain (15 patients; 50%) and lack of energy (13 patients; 45%) among the older children. Total and subscale score agreement varied by proxy type and subscale, ranging from fair to good for most comparisons. Agreement for individual symptoms between the patient and proxy ranged from a kappa of -0.30 (95% confidence interval, -0.43 to -0.01) to 0.91 (95% confidence interval, 0.75 to 1.00). Three of 51 symptomatic patients (6%) had treatment recommendations documented in the electronic health record. CONCLUSIONS: Symptoms are common and cross several functional domains. Proxy and child reports are often not congruent, possibly explaining apparent undertreatment among this group of patients.
BACKGROUND: Systematic symptom assessment is not routinely performed in pediatric oncology. The objectives of the current study were to characterize the symptoms of pediatric oncology outpatients and evaluate agreement between patient and proxy reports and the association between children's ratings and oncologists' treatment recommendations. METHODS: Two versions of the pediatric Memorial Symptom Assessment Scale (pMSAS) were translated into Spanish. An age-appropriate and language-appropriate pMSAS was administered independently before visits to the oncologist to patients and family caregivers (caregivers) and after visits to consenting oncologists. Statistical analysis included Spearman correlation coefficients and weighted kappa values. RESULTS: English and Spanish results were similar and were combined. A total of 60 children and their caregivers completed the pMSAS. The children had a median age of 10 years (range, 7-18 years); approximately 62% were male and 33% were Spanish-speaking. Fourteen oncologists completed the pMSAS for 25 patients. Nine patients (15%) had no symptoms and 38 patients (63%) reported ≥2 symptoms. The most common symptoms were fatigue (12 patients; 40%) and itch (9 patients; 30%) for the younger children and pain (15 patients; 50%) and lack of energy (13 patients; 45%) among the older children. Total and subscale score agreement varied by proxy type and subscale, ranging from fair to good for most comparisons. Agreement for individual symptoms between the patient and proxy ranged from a kappa of -0.30 (95% confidence interval, -0.43 to -0.01) to 0.91 (95% confidence interval, 0.75 to 1.00). Three of 51 symptomatic patients (6%) had treatment recommendations documented in the electronic health record. CONCLUSIONS: Symptoms are common and cross several functional domains. Proxy and child reports are often not congruent, possibly explaining apparent undertreatment among this group of patients.
Authors: Phoebe D Williams; Arthur R Williams; Katherine P Kelly; Carol Dobos; Annie Gieseking; Renee Connor; Lavonne Ridder; Nancy Potter; Deborah Del Favero Journal: Cancer Nurs Date: 2012 Mar-Apr Impact factor: 2.592
Authors: John J Collins; Tom D Devine; Gina S Dick; Elizabeth A Johnson; Henry A Kilham; C Ross Pinkerton; M M Stevens; Howard T Thaler; Russell K Portenoy Journal: J Pain Symptom Manage Date: 2002-01 Impact factor: 3.612
Authors: Eduardo Bruera; Jie S Willey; Patricia A Ewert-Flannagan; Mary K Cline; Guddi Kaur; Loren Shen; Tao Zhang; J Lynn Palmer Journal: Support Care Cancer Date: 2004-10-06 Impact factor: 3.603
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: Molly McFatrich; Jennifer Brondon; Nicole R Lucas; Pamela S Hinds; Scott H Maurer; Jennifer W Mack; David R Freyer; Shana S Jacobs; Justin N Baker; Catriona Mowbray; Mian Wang; Sharon M Castellino; Allison Barz Leahy; Bryce B Reeve Journal: Cancer Date: 2019-09-25 Impact factor: 6.860
Authors: Rebecca Williamson Lewis; Karen E Effinger; Karen Wasilewski-Masker; Ann Mertens; Canhua Xiao Journal: Support Care Cancer Date: 2021-07-06 Impact factor: 3.603
Authors: Bryce B Reeve; Molly McFatrich; Jennifer W Mack; Scott H Maurer; Shana S Jacobs; David R Freyer; Janice S Withycombe; Justin N Baker; Sharon M Castellino; Li Lin; Nicole R Lucas; Pamela S Hinds Journal: J Natl Cancer Inst Date: 2020-11-01 Impact factor: 13.506
Authors: Elizabeth D Cox; Sarah K Dobrozsi; Christopher B Forrest; Wendy E Gerhardt; Harald Kliems; Bryce B Reeve; Nan E Rothrock; Jin-Shei Lai; Jacob M Svenson; Lindsay A Thompson; Thuy Dan N Tran; Carole A Tucker Journal: J Pediatr Date: 2020-11-30 Impact factor: 4.406
Authors: Bryce B Reeve; Molly McFatrich; Li Lin; Nicole R Lucas; Jennifer W Mack; Shana S Jacobs; Janice S Withycombe; Justin N Baker; David R Freyer; Pamela S Hinds Journal: Cancer Date: 2020-12-17 Impact factor: 6.860
Authors: Scott H Maurer; Pamela S Hinds; Bryce B Reeve; Jennifer W Mack; Molly McFatrich; Li Lin; Janice S Withycombe; Shana S Jacobs; Justin N Baker; Sharon M Castellino; David R Freyer Journal: Cancer Date: 2021-07-01 Impact factor: 6.921